Advances in understanding the innate immune‐associated diabetic kidney disease-Reference-Cited by-同舟云学术

Advances in understanding the innate immune‐associated diabetic kidney disease

Published:2021-01-28 Issue:2 Volume:35 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Wan Shengfeng¹,Wan Shengkai²,Jiao Xiaojing¹,Cao Huixia¹,Gu Yue¹,Yan Lei¹,Zheng Yan¹,Niu Peiyuan¹,Shao Fengmin¹

Affiliation:

1. Department of Nephrology Henan Provincial Key Laboratory of Kidney Disease and Immunology Henan Provincial People's Hospital (Zhengzhou University People's Hospital) Zhengzhou China

2. Department of Operations Management Henan Provincial People's Hospital (Zhengzhou University People's Hospital) Zhengzhou China

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202002334R

Reference140 articles.

1. Diabetic Nephropathy: An Overview

2. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040

3. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

4. Diabetic nephropathy – complications and treatment

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease;Journal of Ethnopharmacology;2024-10

2. Circulating inflammatory factors and risk causality associated with type 2 diabetic nephropathy: A Mendelian randomization and bioinformatics study;Medicine;2024-07-12

3. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection;International Journal of Molecular Sciences;2024-04-03

4. Novel Biomarkers for the diagnosis of diabetic nephropathy;CASP J INTERN MED;2024

5. (5R)-5-hydroxytriptolide ameliorates diabetic kidney damage by inhibiting macrophage infiltration and its cross-talk with renal resident cells;International Immunopharmacology;2024-01